



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**  
Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa City



## CERTIFICATE OF PRODUCT REGISTRATION

Pursuant to the provisions of Republic Act (R.A.) No. 3720 as amended, known as the Foods, Drugs, Devices and Cosmetics Act, and consistent with R.A. No. 6675, known as the Generics Act of 1988, and R.A. No. 9711, otherwise known as the Food and Drug Administration Act of 2009, the product described hereunder has been found to conform with the requirements and standards for marketing authorization of pharmaceutical products per existing regulations in force as of date hereof.

**Registration Number** : DR-XY46236

**Generic Name** : Clobetasol propionate

**Brand Name** : Cleovate

**Dosage Strength & Form** : 500 mcg/g (0.05%w/w) Cream

**Pharmacologic Category** : Corticosteroid

**Classification** : Prescription Drug (Rx)

**Approved Shelf-life** : 24 months

**Storage Condition** : Store at temperatures not exceeding 30°C.

**Packaging** : Aluminum Collapsible Tube x 5 g (Box of 1's)

**Manufacturer** : Curetech Skincare  
Plot No.33 & 34, Phase-IV, Bhatoli Kalan, Baddi-173  
205, Distt. Solan (H.P.), India

**For** : Subira Pharmaceuticals Pvt. Ltd.  
A/408 Fairlink Centre CHS, Off Link Road, Andheri  
(W), Mumbai-40053, Maharashtra, India

**Importer** : EON Pharmatek Inc.  
17 3rd St., Kapitolyo, Pasig City

**Distributor** : EON Pharmatek Inc.  
17 3rd St., Kapitolyo, Pasig City

The marketing authorization shall be valid until **01 February 2023** subject to the conditions listed on the reverse side. No change in the formulation, labelling and commercial presentation of this product shall be made at any time during the effectivity of this registration without prior written approval of this Office.

This marketing authorization is subject to suspension, cancellation or recall should any violation of R.A. No. 3720, R.A. No. 6675 and R.A. No. 9711 and/or regulations issued thereunder involving the product be committed.

Witness My Hand and Seal of this Office, this **20 May 2021**.

By Authority of the Director-General  
Per FDA Order No. 2016-005

**JESUSA JOYCE N. CIRUNAY, RPh**  
Director IV  
Center for Drug Regulation and Research

REG. STATUS : Initial (Revalidation)  
AMOUNT : Php15,660; Php1,010.00  
OR NUMBER : 0530689; 0751742  
DATE : 05 Feb. 14; 21 Jun. 16; 17 Apr. 17; 18 Dec. 2019

BAR CODE :  
DOC TRACK :



2 0 1 4 0 1 2 7 1 4 4 1 4 8



Management  
System  
ISO 9001:2015



FDA-0512057



Registration Number : DR-XY46236

**SPECIAL CONDITION:**

Provided that nothing in the registration of the product herein granted shall be interpreted or construed as an endorsement or representation by FDA, that Registrant has the right or privilege to the use of the name or brand so registered; Registrant hereby agrees and affirms to indemnify and/or hold FDA free and harmless against any and all third-party claims on infringement of patent, trademark or intellectual property right arising from the registration of the product.

- |                                     |          |   |
|-------------------------------------|----------|---|
| <input type="checkbox"/>            | <b>A</b> | This is subject to batch notification.  |
| <input type="checkbox"/>            | <b>B</b> | This is subject to lot release certification.   |
| <input type="checkbox"/>            | <b>C</b> | This is subject to compliance with the requirements under FDA Circular No. 2013-004 for Monitored Release (MR) drug products.   |
| <input checked="" type="checkbox"/> | <b>D</b> | Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O No. 2016-0008 for drug products for human use and A.O. No. 105 s. 1991 for veterinary drug products. |
| <input type="checkbox"/>            | <b>E</b> | Submit a satisfactory bioavailability/bioequivalence study report or biowaiver evidence (whichever is applicable) within the validity in accordance with FDA Circular No. 2016-019.   |
| <input type="checkbox"/>            | <b>F</b> | Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a DOH (yellow) prescription form. It is a habit-forming drug.  |
| <input type="checkbox"/>            | <b>G</b> | Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a personalized ordinary prescription. It is a habit-forming drug.  |
| <input type="checkbox"/>            | <b>H</b> | Patient Information Leaflet - Appropriate information for the consumers shall be written in Filipino and/or local dialects, as appropriate.   |
| <input type="checkbox"/>            | <b>I</b> | Submit a Certificate of Good Manufacturing Practice (GMP) Compliance of Foreign Drug Manufacturer(s) within the validity in accordance with A. O. No. 2013-0022 and FDA Circular No. 2014-016.  |
| <input type="checkbox"/>            | <b>J</b> | Review of the submitted Bioequivalence Study Report or Biowaiver, whichever is applicable, shall be completed by this Center within the validity, provided, the CPR shall be revoked if interchangeability is not established.  |
| <input type="checkbox"/>            | <b>K</b> | Subject to satisfactory compliance to the post-approval commitments detailed in the letter accompanying this CPR.   |

**REMARKS:**

This Certificate of Product Registration (CPR) is revalidated to reflect the full validity until 01 February 2023. The post-approval compliance to the issued Certificate of Product Registration (CPR) shall be included in the CDRR product file for reference, this CPR shall be revoked/cancelled if post-approval compliance is not fully complied. This cancels CPR Control No. FDA-0275332 valid until 01 February 2020 and issued on 01 February 2018.